The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Exosomes Increase the Therapeutic Index of Doxorubicin in Breast and Ovarian Cancer Mouse Models
Open accessAbstract
AIM: To demonstrate that exosomes (exo) could increase the therapeutic index of doxorubicin (DOX). MATERIALS & METHODS: Exosomes were characterized by nanoparticle tracking analysis and western blot. Tissue toxicity was evaluated by histopathological analysis and drug efficacy by measuring tumor volume. DOX biodistribution was analyzed by MS. RESULTS: Exosomal doxorubicin (exoDOX) avoids heart toxicity by partially limiting the crossing of DOX through the myocardial endothelial cells. For this reason, mice can be treated with higher concentration of exoDOX thus increasing the efficacy of DOX as demonstrated in breast and ovarian mouse tumors. CONCLUSION: ExoDOX is safer and more effective than free DOX. Importantly, the first spontaneous transformed syngeneic model of high-grade serous ovarian cancer was utilized for providing a new therapeutic opportunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J. J., & Lötvall, J. O. (2007) · Nature Cell Biology · doi:10.1038/ncb1596 · Cited by 12,834
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Extracellular vesicles: Exosomes, microvesicles, and friends
Raposo, G., & Stoorvogel, W. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201211138 · Cited by 8,099
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2011) · Nature Biotechnology · doi:10.1038/nbt.1807 · Cited by 4,930
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
Peinado, H., Alečković, M., Lavotshkin, S., Matei, I., Costa-Silva, B., Moreno-Bueno, G., Hergueta-Redondo, M., Williams, C., García-Santos, G., Ghajar, C. M., et al. (2012) · Nature Medicine · doi:10.1038/nm.2753 · Cited by 3,715
Cited by
Extracellular vesicles in cancer — implications for future improvements in cancer care
Xu, R., Rai, A., Chen, M., Suwakulsiri, W., Greening, D. W., & Simpson, R. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0036-9 · Cited by 1,445
Nanomaterials for cancer therapy: current progress and perspectives
Cheng, Z., Li, M., Dey, R., & Chen, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01096-0 · Cited by 1,168
Gurunathan, S., Kang, M.-H., Jeyaraj, M., Qasim, M., & Kim, J.-H. (2019) · Cells · doi:10.3390/cells8040307 · Cited by 1,122
Nanoparticles for Cancer Therapy: Current Progress and Challenges
Gavas, S., Quazi, S., & Karpiński, T. M. (2021) · Nanoscale Research Letters · doi:10.1186/s11671-021-03628-6 · Cited by 1,069
“Nevertheless, drawbacks like deficiency of standard conditions for exosomal isolation and purification are crucial and need to be addressed [70, 71].”
BackgroundInnovative approaches for cancer treatment: current perspectives and new challenges
Pucci, C., Martinelli, C., & Ciofani, G. (2019) · ecancermedicalscience · doi:10.3332/ecancer.2019.961 · Cited by 814
Isolation and characterization of exosomes for cancer research
Zhu, L., Sun, H.-T., Wang, S., Huang, S.-L., Zheng, Y., Wang, C.-Q., Hu, B.-Y., Qin, W., Zou, T.-T., Fu, Y., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00987-y · Cited by 520
Exosome engineering: Current progress in cargo loading and targeted delivery
Fu, S., Wang, Y., Xia, X., & Zheng, J. C. (2020) · NanoImpact · doi:10.1016/j.impact.2020.100261 · Cited by 444
Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer
Huang, L., Rong, Y., Tang, X., Yi, K., Qi, P., Hou, J., Liu, W., He, Y., Gao, X., Yuan, C., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01515-x · Cited by 401
Exosomes in Cancer Nanomedicine and Immunotherapy: Prospects and Challenges
Syn, N. L., Wang, L., Chow, E. K.-H., Lim, C. T., & Goh, B.-C. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2017.03.004 · Cited by 399
Gurunathan, S., Kang, M.-H., & Kim, J.-H. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s291956 · Cited by 379
Recent progress in targeted delivery vectors based on biomimetic nanoparticles
Chen, L., Hong, W., Ren, W., Xu, T., Qian, Z., & He, Z. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00631-2 · Cited by 374
Niu, W., Xiao, Q., Wang, X., Zhu, J., Li, J., Liang, X., Peng, Y., Wu, C., Lu, R., Pan, Y., et al. (2021) · Nano Letters · doi:10.1021/acs.nanolett.0c04753 · Cited by 372
Shafei, A., El-Bakly, W., Sobhy, A., Wagdy, O., Reda, A., Aboelenin, O., Marzouk, A., El Habak, K., Mostafa, R., Ali, M. A., et al. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.09.059 · Cited by 318
Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming
Mattioli, R., Ilari, A., Colotti, B., Mosca, L., Fazi, F., & Colotti, G. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101205 · Cited by 294
Bioinspired exosome-like therapeutics and delivery nanoplatforms
Lu, M., & Huang, Y. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119925 · Cited by 282
Extracellular vesicles and anti-cancer drug resistance
Namee, N. M., & O'Driscoll, L. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.07.003 · Cited by 274
Emerging Prospects of Exosomes for Cancer Treatment: From Conventional Therapy to Immunotherapy
Nam, G., Choi, Y., Kim, G. B., Kim, S., Kim, S. A., & Kim, I. (2020) · Advanced Materials · doi:10.1002/adma.202002440 · Cited by 267
Exosome as a Novel Shuttle for Delivery of Therapeutics across Biological Barriers
Das, C. K., Jena, B. C., Banerjee, I., Das, S., Parekh, A., Bhutia, S. K., & Mandal, M. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00901 · Cited by 263
Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery
Waheed, S., Li, Z., Zhang, F., Chiarini, A., Armato, U., & Wu, J. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01605-4 · Cited by 259
Exosome-Based Drug Delivery: Translation from Bench to Clinic
Koh, H. B., Kim, H. J., Kang, S.-W., & Yoo, T.-H. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082042 · Cited by 259
Mehryab, F., Rabbani, S., Shahhosseini, S., Shekari, F., Fatahi, Y., Baharvand, H., & Haeri, A. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.06.036 · Cited by 216
Exosomes as bio-inspired nanocarriers for RNA delivery: preparation and applications
Amiri, A., Bagherifar, R., Ansari Dezfouli, E., Kiaie, S. H., Jafari, R., & Ramezani, R. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03325-7 · Cited by 186
“Lower levels of cardiotoxicity along with the higher concentration of intracellular doxorubicin were obtained in doxorubicin-loaded exosomes in contrast to its systemic administration [105].”
BackgroundRecent Advances in Exosome-Based Drug Delivery for Cancer Therapy
Kim, H., Jang, H., Cho, H., Choi, J., Hwang, K. Y., Choi, Y., Kim, S. H., & Yang, Y. (2021) · Cancers · doi:10.3390/cancers13174435 · Cited by 152
“Dox, one of the most effective anti-cancer drugs, is used for the treatment of leukemia, lymphoma, and many types of solid tumors.”
BackgroundInfluentialExosomes in cancer: Use them or target them?
Bastos, N., Ruivo, C. F., da Silva, S., & Melo, S. A. (2018) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2017.08.009 · Cited by 140
“Additionally, ExoDOX is more tolerable than the free drug reducing cardiotoxicity, one of the main doxorubicin side-effects [80].”
BackgroundTargeted delivery of doxorubicin to HER2 positive tumor models
Gomari, H., Forouzandeh Moghadam, M., Soleimani, M., Ghavami, M., & Khodashenas, S. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s210731 · Cited by 111
Extracellular vesicles in cancer nanomedicine
Tarasov, V. V., Svistunov, A. A., Chubarev, V. N., Dostdar, S. A., Sokolov, A. V., Brzecka, A., Sukocheva, O., Neganova, M. E., Klochkov, S. G., Somasundaram, S. G., et al. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.017 · Cited by 97
New perspective into mesenchymal stem cells: Molecular mechanisms regulating osteosarcoma
Chang, X., Ma, Z., Zhu, G., Lu, Y., & Yang, J. (2021) · Journal of Bone Oncology · doi:10.1016/j.jbo.2021.100372 · Cited by 70
Ansari, M. A., Thiruvengadam, M., Venkidasamy, B., Alomary, M. N., Salawi, A., Chung, I.-M., Shariati, M. A., & Rebezov, M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.04.005 · Cited by 63
Cosmetic wastewater treatment technologies: a review
Gkika, D. A., Mitropoulos, A. C., Lambropoulou, D. A., Kalavrouziotis, I. K., & Kyzas, G. Z. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-23045-1 · Cited by 43
Cancer Extracellular Vesicles: Next-Generation Diagnostic and Drug Delivery Nanotools
Palazzolo, S., Memeo, L., Hadla, M., Duzagac, F., Steffan, A., Perin, T., Canzonieri, V., Tuccinardi, T., Caligiuri, I., & Rizzolio, F. (2020) · Cancers · doi:10.3390/cancers12113165 · Cited by 34
Self-citation
Metadata
- Authors
- Hadla, M., Palazzolo, S., Corona, G., Caligiuri, I., Canzonieri, V., Toffoli, G., & Rizzolio, F.
- Venue
- Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2016-08-25
- Volume
- 11
- Issue
- 18
- Pages
- 2431-2441
- ISSN
- 1743-5889 (ISSN-L)
- 1748-6963
- OpenAlex
- W2512006014
- Cited by
- 282
- References
- 44
- FWCI
- 8.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.